国药控股(01099)2025年度营收734.16亿元，经调整净利润109.57亿元

公告速递

Yesterday

本季度信息

根据公告披露，国药控股旗下国药集团一致药业股份有限公司（下称“国药一致”）在截至2025年12月31日止年度实现营业收入734.16亿元，同比下降1.29%。经营利润达到15.13亿元，同比增幅163.80%。经调整后（扣除非经常性损益）归属于上市公司股东的净利润为109.57亿元，同比上涨88.53%。公告指出，报告期内利润增长主要由于商誉及无形资产减值计提同比减少，以及人力与租金等刚性费用随门店调整而下降所致。

业务分项

分销板块在报告期内实现营业收入533.21亿元，同比增长0.64%，并实现净利润9.49亿元，同比增长2.94%。零售板块（国药控股国大药房有限公司）同期营业收入为209.81亿元，同比下降6.16%。净利润则录得-2.17亿元，但在商誉和无形资产减值影响剔除后，该板块实现净利润0.60亿元，同比大幅增长139.28%。公告强调了优化产品结构和门店战略调整等措施对经营质量提升带来的积极影响。

下个财报期展望

公告提及，2026年是“十五五”规划的开局之年，亦是国药一致深化转型、迈向高质量发展的关键时期。公司将继续聚焦“开源、节流、提效”的重点方向，力求在复杂多变的外部环境中保持战略定力，推动各项经营指标稳中向好。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1191540618"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1191540618\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1191540618?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-03-18 06:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191540618","market":"us","top_or_hot":-1,"title":"国药控股(01099)2025年度营收734.16亿元，经调整净利润109.57亿元","media":"公告速递","content":"<p>本季度信息</p>\n<p>根据公告披露，国药控股旗下国药集团一致药业股份有限公司（下称“国药一致”）在截至2025年12月31日止年度实现营业收入734.16亿元，同比下降1.29%。经营利润达到15.13亿元，同比增幅163.80%。经调整后（扣除非经常性损益）归属于上市公司股东的净利润为109.57亿元，同比上涨88.53%。公告指出，报告期内利润增长主要由于商誉及无形资产减值计提同比减少，以及人力与租金等刚性费用随门店调整而下降所致。</p>\n<p>业务分项</p>\n<p>分销板块在报告期内实现营业收入533.21亿元，同比增长0.64%，并实现净利润9.49亿元，同比增长2.94%。零售板块（国药控股国大药房有限公司）同期营业收入为209.81亿元，同比下降6.16%。净利润则录得-2.17亿元，但在商誉和无形资产减值影响剔除后，该板块实现净利润0.60亿元，同比大幅增长139.28%。公告强调了优化产品结构和门店战略调整等措施对经营质量提升带来的积极影响。</p>\n<p>下个财报期展望</p>\n<p>公告提及，2026年是“十五五”规划的开局之年，亦是国药一致深化转型、迈向高质量发展的关键时期。公司将继续聚焦“开源、节流、提效”的重点方向，力求在复杂多变的外部环境中保持战略定力，推动各项经营指标稳中向好。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>国药控股(01099)2025年度营收734.16亿元，经调整净利润109.57亿元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n国药控股(01099)2025年度营收734.16亿元，经调整净利润109.57亿元\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1097772564\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">公告速递 </p>\n<p class=\"h-time\">2026-03-18 06:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>本季度信息</p>\n<p>根据公告披露，国药控股旗下国药集团一致药业股份有限公司（下称“国药一致”）在截至2025年12月31日止年度实现营业收入734.16亿元，同比下降1.29%。经营利润达到15.13亿元，同比增幅163.80%。经调整后（扣除非经常性损益）归属于上市公司股东的净利润为109.57亿元，同比上涨88.53%。公告指出，报告期内利润增长主要由于商誉及无形资产减值计提同比减少，以及人力与租金等刚性费用随门店调整而下降所致。</p>\n<p>业务分项</p>\n<p>分销板块在报告期内实现营业收入533.21亿元，同比增长0.64%，并实现净利润9.49亿元，同比增长2.94%。零售板块（国药控股国大药房有限公司）同期营业收入为209.81亿元，同比下降6.16%。净利润则录得-2.17亿元，但在商誉和无形资产减值影响剔除后，该板块实现净利润0.60亿元，同比大幅增长139.28%。公告强调了优化产品结构和门店战略调整等措施对经营质量提升带来的积极影响。</p>\n<p>下个财报期展望</p>\n<p>公告提及，2026年是“十五五”规划的开局之年，亦是国药一致深化转型、迈向高质量发展的关键时期。公司将继续聚焦“开源、节流、提效”的重点方向，力求在复杂多变的外部环境中保持战略定力，推动各项经营指标稳中向好。</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01099","symbol_name":"国药控股","start_time":0,"source_url":"","article_id":"1191540618","we_media_id":"1097772564","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191540618","pubTimestamp":1773785800,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"公告速递","introduction":"港美股公告全覆盖","home_visible":1,"id":"1097772564","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"根据公告披露，国药控股旗下国药集团一致药业股份有限公司在截至2025年12月31日止年度实现营业收入734.16亿元，同比下降1.29%。经营利润达到15.13亿元，同比增幅163.80%。经调整后归属于上市公司股东的净利润为109.57亿元，同比上涨88.53%。公告指出，报告期内利润增长主要由于商誉及无形资产减值计提同比减少，以及人力与租金等刚性费用随门店调整而下降所致。公告提及，2026年是“十五五”规划的开局之年，亦是国药一致深化转型、迈向高质量发展的关键时期。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"01099":"国药控股"},"translate_title":"Sinopharm Holdings (01099) 2025 revenue of 73.416 billion yuan, adjusted net profit of 10.957 billion yuan","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01099":1},"content_text":"本季度信息\n根据公告披露，国药控股旗下国药集团一致药业股份有限公司（下称“国药一致”）在截至2025年12月31日止年度实现营业收入734.16亿元，同比下降1.29%。经营利润达到15.13亿元，同比增幅163.80%。经调整后（扣除非经常性损益）归属于上市公司股东的净利润为109.57亿元，同比上涨88.53%。公告指出，报告期内利润增长主要由于商誉及无形资产减值计提同比减少，以及人力与租金等刚性费用随门店调整而下降所致。\n业务分项\n分销板块在报告期内实现营业收入533.21亿元，同比增长0.64%，并实现净利润9.49亿元，同比增长2.94%。零售板块（国药控股国大药房有限公司）同期营业收入为209.81亿元，同比下降6.16%。净利润则录得-2.17亿元，但在商誉和无形资产减值影响剔除后，该板块实现净利润0.60亿元，同比大幅增长139.28%。公告强调了优化产品结构和门店战略调整等措施对经营质量提升带来的积极影响。\n下个财报期展望\n公告提及，2026年是“十五五”规划的开局之年，亦是国药一致深化转型、迈向高质量发展的关键时期。公司将继续聚焦“开源、节流、提效”的重点方向，力求在复杂多变的外部环境中保持战略定力，推动各项经营指标稳中向好。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,SGX","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}